IN BRIEF: Thalia Therapeutics eyes adding microRNA therapeutic asset

Related news

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at £1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at £7,264 versus £7,282. Research and development costs fall to £214,120 from £390,387 and general and administration costs rise to £1.0 million from £837,996. ‘Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company’s portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company,’ says Chief Executive David Solomon.

Current stock price: 0.55 pence

12-month change: up 45%

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Bids, mergers and takeovers

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.